PDCD1 and neoplasm: An immunosuppressive tumor microenvironment, a paucity of T cells in tumors (so called immunologically “cold” tumors) and low tumor-mutational burden have all been suggested to contribute to the observed suboptimal therapeutic effects of anti-PD-1/PD-L1 therapies (8).